These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 11895198)

  • 1. Arsenic trioxide in multiple myeloma: rationale and future directions.
    Anderson KC; Boise LH; Louie R; Waxman S
    Cancer J; 2002; 8(1):12-25. PubMed ID: 11895198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arsenic trioxide: an emerging therapy for multiple myeloma.
    Munshi NC
    Oncologist; 2001; 6 Suppl 2():17-21. PubMed ID: 11331436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-biomodulation with arsenic trioxide in multiple myeloma.
    Gallagher RE
    Leuk Res; 2001 Mar; 25(3):237-9. PubMed ID: 11226520
    [No Abstract]   [Full Text] [Related]  

  • 4. Trials of arsenic trioxide in multiple myeloma.
    Hussein MA
    Cancer Control; 2003; 10(5):370-4. PubMed ID: 14581891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical activity of arsenic trioxide for the treatment of multiple myeloma.
    Munshi NC; Tricot G; Desikan R; Badros A; Zangari M; Toor A; Morris C; Anaissie E; Barlogie B
    Leukemia; 2002 Sep; 16(9):1835-7. PubMed ID: 12200700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nontraditional cytotoxic therapies for relapsed/refractory multiple myeloma.
    Hussein MA
    Oncologist; 2002; 7 Suppl 1():20-9. PubMed ID: 11961206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia.
    Soignet SL
    Oncologist; 2001; 6 Suppl 2():11-6. PubMed ID: 11331435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future.
    Evens AM; Tallman MS; Gartenhaus RB
    Leuk Res; 2004 Sep; 28(9):891-900. PubMed ID: 15234563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
    Leu L; Mohassel L
    Am J Health Syst Pharm; 2009 Nov; 66(21):1913-8. PubMed ID: 19850784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide.
    Slack JL; Waxman S; Tricot G; Tallman MS; Bloomfield CD
    Oncologist; 2002; 7 Suppl 1():1-13. PubMed ID: 11961204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma.
    Kalmadi SR; Hussein MA
    Acta Haematol; 2006; 116(1):1-7. PubMed ID: 16809883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arsenic trioxide: a new immunomodulatory agent in the management of multiple myeloma.
    Hussein MA
    Med Oncol; 2001; 18(4):239-42. PubMed ID: 11918450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arsenic trioxide in hematological malignancies: the new discovery of an ancient drug.
    Bonati A; Rizzoli V; Lunghi P
    Curr Pharm Biotechnol; 2006 Dec; 7(6):397-405. PubMed ID: 17168655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the mitochondria: an exciting new approach to myeloma therapy. Commentary re: N. J. Bahlis et al., Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin. Cancer Res., 8: 3658-3668, 2002.
    Dalton WS
    Clin Cancer Res; 2002 Dec; 8(12):3643-5. PubMed ID: 12473572
    [No Abstract]   [Full Text] [Related]  

  • 15. Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent.
    Amadori S; Fenaux P; Ludwig H; O'dwyer M; Sanz M
    Curr Med Res Opin; 2005 Mar; 21(3):403-11. PubMed ID: 15811209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arsenic trioxide.
    Litzow MR
    Expert Opin Pharmacother; 2008 Jul; 9(10):1773-85. PubMed ID: 18570609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arsenic compounds in the treatment of multiple myeloma: a new role for a historical remedy.
    Berenson JR; Yeh HS
    Clin Lymphoma Myeloma; 2006 Nov; 7(3):192-8. PubMed ID: 17229334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arsenic trioxide and acute promyelocytic leukemia: clinical and biological.
    Chen Z; Zhao WL; Shen ZX; Li JM; Chen SJ; Zhu J; Lallemand-Breittenbach V; Zhou J; Guillemin MC; Vitoux D; de Thé H
    Curr Top Microbiol Immunol; 2007; 313():129-44. PubMed ID: 17217042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trials referral resource. Clinical trials with arsenic trioxide.
    Murgo AJ; McBee WL; Cheson BD
    Oncology (Williston Park); 2000 Feb; 14(2):206, 211, 215-6 passim. PubMed ID: 10736809
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma.
    Hussein MA; Saleh M; Ravandi F; Mason J; Rifkin RM; Ellison R
    Br J Haematol; 2004 May; 125(4):470-6. PubMed ID: 15142117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.